RDB07407 - pGL4-phCHEK2

Please review the QC test results indicated by check

icon below as well as clone information before placing your order.

pGL4-phCHEK2 (#RDB07407)

Promoter collection, Human CHEK2 promoter

Alternative name	U2769(2147)-3
Clone info.	PCR amplified human CHEK2 promoter sequence was inserted into a firefly luciferase vector. Cloned fragment: 28743124 to 28741813(NC_000022.11); relatively -1290 to +22, where +1 corresponds to 1 nt of NM_007194.3.
Comment	PCR cloning, forward primer: TGGCCCCTCTACAAGATGGT; reverse primer: AGCAGAGTGGCGCTAAACCT. Entire sequence of promoter region has not been confirmed.
Vector backbone	pGL4.10 [Luc2] (Plasmid)
Selectable markers	Amp^r
Gene/insert name	Human CHK2 checkpoint homolog genomic DNA
Depositor\|Developer	DNA Bank, \|

Remarks, protocol and/or map (pdf)	RDB07407.pdf

Distribution information

Please check terms and conditions set forth by the depositor, which are specified in the RIKEN BRC Catalog and/or Web Catalog.

Ordering forms
Order form [Credit Card Payment] [Bank Transfer Payment] [Example of order form ]
MTA, for use for not-for-profit academic purpose [Word] [Example of MTA ]
Please visit Information of Request for Distribution.[link]

Terms and conditions for distribution In publishing the research results to be obtained by use of the BIOLOGICAL RESOURCE, an acknowledgment to the DEPOSITOR is requested.
Additional terms and conditions:
The use of the BIOLOGICAL RESOURCE is restricted to the academic researches conducted by non-profit organization. By using this material, the RECIPIENT agrees to be bound by the conditions of the limited use statement of the Promega Corporation.

提供案内 (日本国内) [open/close]

Ordering forms	Order form [Credit Card Payment] [Bank Transfer Payment] [Example of order form ] MTA, for use for not-for-profit academic purpose [Word] [Example of MTA ] Please visit Information of Request for Distribution.[link]
Terms and conditions for distribution	In publishing the research results to be obtained by use of the BIOLOGICAL RESOURCE, an acknowledgment to the DEPOSITOR is requested. Additional terms and conditions: The use of the BIOLOGICAL RESOURCE is restricted to the academic researches conducted by non-profit organization. By using this material, the RECIPIENT agrees to be bound by the conditions of the limited use statement of the Promega Corporation.

必要書類	提供依頼書 [依頼書の記入例 ] 提供同意書 (MTA, 非営利学術目的用)[Word] [MTAの記入例 ] 手続きの概要は、「提供申込みについて[link]」をご覧ください。
MTAに書く使用条件	謝辞の表明を必要とする。 MTAに書く付加的使用条件：本件リソースの使用は学術機関での学術研究に限る。本件リソースの使用にあたって、利用者はプロメガ社の限定使用条件に従う必要がある。

Catalog #	Resource name	Shipping form	Fee (non-profit org.)
RDB07407	pGL4-phCHEK2	DNA solution

Please review the QC test results indicated by check

icon below as well as clone information before placing your order.

How to cite this biological resource

Materials & Methods section:

The pGL4-phCHEK2 was provided by the RIKEN BRC through the National BioResource Project of the MEXT, Japan (cat. RDB07407).

Reference section:

Further references such as user reports and related articles (go to bottom)

QC test results

RIKEN BRC has sequenced portions of this material for quality test.
Please review the QC test results indicated by check icon as well as clone information before placing your order.

Test sheet	RDB07407_A9Gvp1-1.pdf

Nucleotide sequence of a portion of this resource (if available).

Primer: pGL4ins_F () Region: pause site,insert5' Sequence file: RDB07407_A9Gva.seq
>07407_07407_A9Gv_1_pGL4ins_F_A11_02_ABI24.ab1 1 NNNNNNNNNN NNNNNANNNN NANTNNNNNG TCCCCNGTGC AAGTGCAGGT GCCAGAACAT 61 TTCTCTGGCC TAACTGGCCG GTACCTGAGC TCGCTAGCCT CGAGGATTGG CCCCTCTACA 121 AGATGGTCTT GAAGAAAGTC TTTCTGGTGC TTGAACAAGT GTGACTGAAT CATGTTTTCT 181 TTAATACCAC CCTAACTTTT CCACGGCCCA GGTCCCTTCA TCCCTGTCTC TCCCGGTTTA 241 TTTTAATTCA GCCCCTTTCA CATTCTACTC CCAGAGTCTG TCCTATTTCC TTACCAGTTC 301 AGCTCTATCC ACACTGCCCC GTCTCTCCAA GAACCTCAGT CTCAGGGGGA AAAACCATTT 361 ATTGGACCCT CTCCCTCCAA TTCTCACTTT TCCCTCAGGC CTCGCCCACA ATATTAAGCT 421 TTTCATGCTT TACTCCCTAA TCTCGGATCA CACTTCTGCA GTCCTTTCTT AAATACATCA 481 ACCCAACTTT AAACCTTACT CACCCTATTC ATTCAAGTCT TCCAGTCTCC CAGGCCCTGC 541 CCCTCAAGTA CCCTTTCCTC AAGTTCCGCC CCTCGACTTC TCCTTCCCTT TCCCGTAGGT 601 ACCGCCCCTC AAATCTCCCT CCCCTCTAGC CTCGGCCCCC CTATTTCCTC TAACTTCAGC 661 GCCCGCCCCT CCAGTCCCGT TCGTCTCCCT TCTCCACACC TCAACGTTGC TTCCCTCAGT 721 CCCCGCCTCT CAATTTCCTC CTGAGAAATC AAGACACTTC TCTCACGCCT GCTCTCTAGA 781 CCTCCGCCCC CCCATCANTC CCGCCTTCTC TTCCGCCAGC CAGATCCGTC CTCCCCTCTC 841 GCANGCCANA NCTCGACGNG TCTCNCGCNN GGGCCCGTTN NCCGAAACNG NCGCTCGNAN 901 CAGTNCATNA N //
Primer: pGL4ins_R () Region: insert3' Sequence file: RDB07407_A9Gvb.seq
>07407_07407_A9Gv_1_pGL4ins_R_B11_05_ABI24.ab1 1 NNNNNNNNNN NNNNNNNGNN NNNNGGCGCT NGGCCCTTCT TANTGTTTTT GGCATCTTCN 61 NTGGTGGCTT TACCNACAGT ACCGGATTGC CAAGCTTGGC CGCCGAGGCC AGATCTTGAT 121 AGCAGAGTGG CGCTAAACCT GCAGATACAA ACTCCACCCT CAGCCAATCA AAACCCCCTC 181 CCCTGCCGCC GGACCAATGA GGAGCAGCAG ATGTGGCCGT CAGGCGCCGC CTCAATGCCT 241 CCTGGGAGTT GTAGTTTAGA AGGGAGAGCG GAACTTAGAA CCCGGGTTCC CCTCGGGTGA 301 TCCCGCCCCC TCGACTCCCC AGCCAATCAG CAACATTAGT CTGGTTAGAC GCTCTCTTTG 361 CTTTTCCCCA CGAGTGACCA CGGCTAGATA GGCCGCCGGC CAGATGTGGC GGGGGAGAGC 421 CGGGGCTTTG CTCCGGGTGT GGGGGTTTTG GCCGACAGGG GTTCCCAGAA GGAGACCGCT 481 AAGCTGCGAT GCTGCGTCGC AGGCGGGAAG CAATTATCCC CGCTGTTGGA ACTGCGGCGG 541 CCCATGGGGC CCCGGGCGGG AGGACAGGTT CTTCTGCCCA CAGTGCCGAG CGCTGCAGGC 601 ACCTGACCCC ACTCGAGACT ACTTCAGCCT TATGGACTGG TACGAGCGAC GGTTTCGGGA 661 AACGGGCCCG GGCGAGAGAC ACGTCGAGGT CTGGCCTGCG AGAGGGGANG ANGGATCTGG 721 CTGGCGGAAG AGAANGCGGG ACTGATGGGG GGGCGGANGT CTAGAGAGCA GGCGTGAGAG 781 AAGTGTCTTG ATTTCTCANG ANGAAATTGA GANGCGGGGA CTGNNGGAAG CAACGTTGAN 841 GTGTGGAGAA NGGANACGAA CGGGACTGNN NNNGCGGGCG CTGANGTTAG AGGAAATANG 901 GGGGGCCGN //
Primer: pGL4pA_R () Region: SV40p(A),Luc Sequence file: RDB07407_A9Gvc.seq
>07407_07407_A9Gv_1_pGL4pA_R_C08_08_ABI24.ab1 1 NNNNNNNNNN NNNNNNNNTT NTCGNNTTNN CNNNNTTTGT AGAGGTTTTA CTTGCTTTAA 61 AAAACCTCCC ACACCTCCCC CTGAACCTGA AACATAAAAT GAATGCAATT GTTGTTGTTA 121 ACTTGTTTAT TGCAGCTTAT AATGGTTACA AATAAAGCAA TAGCATCACA AATTTCACAA 181 ATAAAGCATT TTTTTCACTG CATTCTAGTT GTGGTTTGTC CAAACTCATC AATGTATCTT 241 ATCATGTCTG CTCGAAGCGG CCGGCCGCCC CGACTCTAGA ATTATTACAC GGCGATCTTG 301 CCGCCCTTCT TGGCCTTAAT GAGAATCTCG CGGATCTTGC GGGCGTCCAA CTTGCCGGTC 361 AGTCCTTTAG GCACCTCGTC CACGAACACA ACACCACCGC GCAGCTTCTT GGCGGTTGTA 421 ACCTGGCTGG CCACATAGTC CACGATCTCC TTCTCGGTCA TGGTTTTACC GTGTTCCAGC 481 ACGACGACTG CGGCGGGCAG CTCGCCGGCA TCGTCGTCGG GCAGGCCGGC GACCCCGGCG 541 TCGAAGATGT TGGGGTGTTG CAGCAGGATG CTCTCCAGTT CGGCTGGGGC TACCTGGTAG 601 CCCTTGTATT TGATCAGGCT CTTCAGCCGG TCCACGATGA AGAAGTGCTC GTCCTCGTCC 661 CAGTAGGCGA TGTCGCCGCT GTGCAGCCAG CCGTCCTTGT CGATGAGAGC GTTTGTAGCC 721 TCGGGGTTGT TAACGTAGCC GCTCATGATC ATGGGGCCAC GGACGCACAG CTCGCCGCGC 781 TGGTTCACAC CCAGTGTCTT ACCGGTGTCC AAGTCCACCA CCTTANCCTC GAAGANNGGC 841 ACCACCTNNN CTACTGCGCC AGGCTTGNCG TCCCCTTCGG GGGNGANCAG AATGGCGCTG 901 GTTGTTTCT //

Please visit Sequencing and PCR primers for primer information.

References

Original, user report and related articles

Resource search

Link

Other resources in our bank

human CHK2 checkpoint homolog

External Database
Human CHK2 checkpoint homolog

Reference sequence